Vaxchora has been available in the US since 2016, when it was the first vaccine to be approved by the FDA to protect against diarrhoeal disease caused by Vibrio cholerae serogroup O1, the globally ...

The global cholera vaccine market is driven by several factors, including the rising frequency of cholera outbreaks, especially in regions with poor sanitation and limited access to clean water.

Probiotics are emerging as a promising adjunctive therapy, offering significant potential in addressing antibiotic-resistant Vibrio cholerae strains. Incorporating probiotics into existing management ...

1 Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, China 2 The First School of Clinical Medicine, Gannan Medical University, Ganzhou, China ...